SAN DIEGO, Dec. 2, 2015 /PRNewswire/ -- OncoSec Medical Incorporated ("OncoSec") (NASDAQ: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, announced today that CEO and President Punit Dhillon will present a corporate overview at Investment Community Visibility (ICV) Manhattan on Tuesday, December 8, 2015 in New York City. The presentation is scheduled to begin at 1:45 PM ET at the Mandarin Oriental Hotel.
ICV Manhattan provides a platform for approximately 50 chief executives at innovative growth companies to meet and share ideas with members of ICV's investment community. This two-day event will allow family office and fund investors to capitalize on new ideas and businesses that are shaping the future of traditional industries. In addition to company presentations, experts will discuss the current landscape of their respective fields through participation in thought leader panels and roundtable discussions. For more information, please visit: http://www.icvevents.com/.
About OncoSec Medical Incorporated OncoSec is a biotechnology company developing DNA-based intratumoral immunotherapies with an investigational technology, ImmunoPulse™, for the treatment of cancer. ImmunoPulse™ is designed to enhance the local delivery and uptake of DNA-based immune-targeting agents, such as IL-12. In Phase I and II clinical trials, ImmunoPulse™ IL-12 has demonstrated a favorable safety profile and evidence of anti-tumor activity in the treatment of various skin cancers as well as the potential to initiate a systemic immune response. OncoSec's lead program, ImmunoPulse™ IL-12, is currently in Phase II development for several indications, including metastatic melanoma, squamous cell carcinoma of the head and neck, and triple-negative breast cancer. In addition to ImmunoPulse™ IL-12, the Company is also identifying and developing new immune-targeting agents for use with the ImmunoPulse™ platform. For more information, please visit www.oncosec.com.
Contact Investor Relations: Jordyn Kopin OncoSec Medical Incorporated 855-662-6732 email@example.com
Media Relations: Mary Marolla OncoSec Medical Incorporated 855-662-6732 firstname.lastname@example.org
SOURCE OncoSec Medical Incorporated